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ABSTRACT  
Despite strong support for the provision of memory assessment services (MASs) in England 
and other countries, their effectiveness in improving patient outcomes is uncertain. We 
aimed to describe change in patients’ health related quality of life (HRQL) six months after 
referral to MASs and to examine associations with patient characteristics and use of post-
diagnostic interventions. 
Data from 883 patients referred to 69 MASs and their informal caregivers (n=569) were 
collected at referral and 6 months later. Multivariable linear regression was used to examine 
associations of change in HRQL (DEMQOL, DEMQOL-Proxy) with patient characteristics (age, 
sex, ethnicity, socioeconomic deprivation and comorbidity) and use of post-diagnostic 
interventions (anti-dementia medications and non-pharmacological therapies). 
Mean HRQL improved, irrespective of diagnosis: self-reported HRQL increased 3.4 points 
(95% CI 2.7 to 4.1), proxy-reported HRQL 1.3 points (95% CI 0.5 to 2.1). HRQL change was 
not associated with any of the patient characteristics studied. Patients with dementia (54%) 
receiving anti-dementia drugs reported greater improvement in their HRQL but those using 
non-pharmacological therapies reported less improvement than those not.  
HRQL improves in the first 6 months after referral to MASs. Research is needed to 
determine longer-term sustainability of the benefits and the cost-effectiveness of MASs. 
KEY WORDS: Dementia; Memory Assessment Services; Memory Clinics; Post-diagnostic 
interventions; Health-related Quality of Life 
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INTRODUCTION 
Over the past decade, there has been a significant increase in the provision of memory 
assessment services (MASs) in England and in other countries.1 MASs, frequently referred to 
as memory clinics, are ambulatory clinics that provide an integrated multi-professional 
approach.2 Their activities include: diagnostic assessment of new referrals; provision of 
post-diagnostic support (both pharmacological and non-pharmacological); and follow-up.3-6  
By 2014, it was estimated that approximately £125m a year was spent on MASs in England.1  
Despite strong support for their introduction, it has been recognised that the effectiveness 
of MASs in improving patient outcomes is uncertain.7 In a recent review of the evidence, 
Banerjee concluded that there is a “lack of studies that have evaluated the absolute and 
relative impact of different models of diagnostic services or the impact of diagnosis and 
stage of illness at diagnosis.”8 This partly reflects the methodological challenges of 
evaluating a complex intervention that not only includes a wide range of diagnostic and 
therapeutic components but also one in which the components vary between MASs. 
Research has therefore either focused on single components,9,10 on a single MAS 11 or have 
focused on patients’ experiences and satisfaction.12-16  
The aims of this study were: to describe the change in health related quality of life (HRQL) 
over the first 6 months after first referral to MAS; to assess whether patient characteristics, 
including diagnosis, are associated with changes in HRQL; and to determine if use of anti-
dementia drugs and non-pharmacological post-diagnostic therapies are associated with 
improved HRQL among those patients diagnosed with dementia.  
METHODS  
Sampling   
5 
Initially, 80 MASs were randomly selected from 212 clinics identified by the Royal College of 
Psychiatrists in their national survey.1 The survey is thought to have identified virtually all 
services in the country, through a review of existing registers, internet searches, and direct 
contact with NHS Trusts and key individuals from each Trust (clinical audit leads, chief 
executives and medical directors). Subsequently two MASs did not participate, five recruited 
fewer than six patients each and were excluded, and four sites did not take part in follow-up 
data collection at 6 months, leaving 69 MASs retained at 6 month follow up.17 The selected 
services were representative of all MASs in England based on data from the national survey: 
number of new referrals per month (63 vs. 72 nationally); mean waiting time for first 
appointment (5.8 vs. 5.2 weeks); and accredited by the Royal College of Psychiatrists (26% 
vs. 30%).1 
Patients referred for a first appointment between September 2014 and April 2015 and their 
informal caregivers (if present) were eligible for inclusion in the study, provided they had 
enough English language to understand the consent process and complete the 
questionnaires. Each site recruited consecutive referrals until 25 patients were included 
(maximum number of 25 patients per site chosen based on the sample size requirements). 
Details have been reported elsewhere.17 
Data collection procedures  
Questionnaires were completed by patients (interviewer administered) and their informal 
caregiver (self-administered) at the time of first referral and 6 months later.  Data on 
patients' socio-demographic characteristics were collected at baseline, including: age 
(categorised as <75 years, 75-79 years, 80-84 years, ≥85 years); ethnicity (white or other); 
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socio-economic status (quintiles of the national ranking of Index of Multiple Deprivation 
scores based on patients’ residential postcodes).18  
The patient questionnaire included disease-specific (DEMQOL 19) and generic (EQ-5D-3L 20) 
HRQL instruments. DEMQOL is a 28-item instrument developed for the UK population.  Each 
item is scored on a four-point scale, with a higher score indicating better HRQL. We used a 
scoring algorithm based on modern psychometric methods (Rasch Measurement Theory) to 
generate scores.21 For analysis, the scores derived using this algorithm (referred to as 
equated scores) were linearly transformed to range from 0 to 100. The EQ-5D-3L has five 
items, each covering one domain: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each item has three levels of response. A summary EQ-5D-3L index 
score was calculated using value sets derived from a UK general population survey to weight 
and combine responses.22 A score of 0 represents death and 1 represents perfect health, 
with scores less than 0 permitted.  
Informal caregivers completed a proxy-reported disease specific instrument of the patient’s 
HRQL (DEMQOL-Proxy) and also a proxy-reported generic HRQL instrument (EQ-5D-3L 
proxy).  DEMQOL-Proxy has 31 items with responses on the same four-point scale as 
DEMQOL; equated scores were derived using the revised scoring algorithm described 
above.21 EQ-5D-3L proxy has the same items as self-reported EQ-5D-3L and is scored in the 
same way. Carers also completed questions on the patient’s use of health and social care 
services in the past month. 
Interviewers extracted data from the patient's record on whether the patient had any pre-
specified comorbid conditions (heart disease, high blood pressure, problems caused by 
stroke, leg pain due to poor circulation, lung disease, diabetes, kidney disease, diseases of 
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the nervous system, liver disease, cancer within the last 5 years, depression or arthritis, 
based on an existing instrument 23). The number of comorbidities was categorised as: 0, 1, 2 
and 3 or more. In addition, data on cognitive function at baseline were extracted from the 
records and used to derive a three-category cognitive function variable based on tertiles of 
Mini-Mental State Examination (MMSE) score 24: category 1 (lowest function) equivalent to 
MMSE score <24, category 2 MMSE score 24-27 and category 3 (highest function) MMSE 
score ≥28. The tertile cut offs were also justified on the basis of established cut offs 
supportive of a diagnosis of dementia at a score of <24.25 
Additionally at 6 month follow up, interviewers extracted information on the patient's 
diagnosis, if one had been made, and informal caregivers provided information on the anti-
dementia medications the patient had taken during the preceding four weeks and receipt of 
any non-pharmacological therapies, such as cognitive behaviour therapy, music and/or 
dance therapy, animal assisted therapies, social engagement groups, walking groups, life 
story work, peer support groups, befriending services, memory cafes and reminiscence 
therapy. At 6 months most interviews (96%) were conducted in the participant’s home, with 
a small minority conducted at the MAS.  
Statistical analysis 
Chi-squared tests were used to compare baseline characteristics of respondents at 6 months 
with those of non-respondents. Patient characteristics were summarized as means and 
standard deviations (SDs) or percentages. Change in each measure of HRQL was assessed 
using paired t-tests to compare mean scores at baseline and 6 months. Changes in HRQL 
among patients with and without a diagnosis and by diagnostic category (dementia, MCI, 
other, none) were compared using t-tests for difference in means and linear regression. 
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Multivariable linear regression was used to examine the relationships between patient 
characteristics and change in HRQL (DEMQOL and DEMQOL-Proxy) at 6 months, with 
adjustment for patient characteristics (age, sex, ethnicity, socioeconomic status, 
comorbidities, diagnosis) and HRQL score at baseline to estimate adjusted differences in 
HRQL change. Clustering of patients within MASs was taken into account by using robust 
(clustered) standard errors. Linear regression was also used to assess the relationships 
between post-diagnostic service use (anti-dementia drugs and non-pharmacological 
therapies) and change in HRQL in patients diagnosed with dementia, adjusting for patient 
characteristics, cognitive function and HRQL at baseline, and each other (non-
pharmacological therapies in the case of anti-dementia drugs and vice versa). Due to 
clustering of the use of non-pharmacological interventions in only around half of all sites, 
we adjusted for clinic as a random effect. Results of linear regression models are presented 
as adjusted differences in HRQL change score with 95% CIs (with Bonferroni adjustment for 
multiple testing; family-wise error rate of 0.05 per model divided by the number of tests).  
To assess the effects of early or late follow-up on outcomes, sensitivity analyses were 
conducted excluding data from 166 participants followed up at <5 or >9 months after 
baseline, or with unknown date of follow up.  
All analyses were conducted using Stata V.14 (StataCorp, College station, Texas, USA). 
Ethical approval 
The study protocol was approved by the National Research Ethics Service Committee 
London (reference: 14/LO/1146) and the London School of Hygiene & Tropical Medicine 
ethics committee (reference: 8418). 
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RESULTS  
Recruitment and response 
Participants recruited into the study at baseline were slightly younger and had a higher 
proportion of men when compared with referrals who did not take part in the study, but 
there was no significant difference in socio-economic status.17 Comparison with cognitive 
function data from eight clinics for all new referrals over the study recruitment period 
(n=617 patients) also indicated that patients with lowest cognitive function were slightly 
underrepresented in our sample.  
Of the 1318 patients eligible for follow up at six months (944 of whom had carers also 
recruited), 883 (67%) patients and 569 (60%) carers completed questionnaires at 6 months 
and form the main analysis sample in this study (flow chart showing sample sizes is 
presented in Supplemental Figure 1).  Of these, 306 patients with a diagnosis of dementia 
and data on use of post-diagnostic interventions were included in sub-group analyses of 
patients with dementia. 
The mean duration of follow up was 6.5 months (SD 0.8; 98% between 5 and 9 months). 
Respondents at 6 months were similar to non-respondents for most characteristics 
measured at baseline (age, sex, ethnicity, co-morbidities, self-reported HRQL (DEMQOL and 
EQ-5D), proxy-reported HQL (EQ-5D Proxy), and whether or not they were accompanied by 
a carer who consented into the study). However, respondents were less likely to be from 
the most deprived areas (14% v 21%, p<0.001), less likely to have low cognitive function 
(MMSE score<24) (39% v 50%, p=0.003), and had higher DEMQOL-Proxy scores (44.2 v 41.8, 
p=0.004). Less than 7% of data were missing for all variables except cognitive function (20% 
missing). Cognitive function data were more likely to be missing among those with no 
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comorbidity (31% v 18% missing, p=0.001) and those who were not using non-
pharmacological therapies (21% v 11% missing, p=0.021), but was not associated with any 
other patient characteristics including diagnosis and HRQL at baseline or 6 months 
(DEMQOL and DEQMOL-Proxy scores). Patients with a proxy in the study were more likely to 
be male (53% v 40%, p<0.001) and to have a diagnosis of dementia (58% v 42%, p<0.001) 
compared to those without a participating carer, but there was no difference in age, 
ethnicity, SES, comorbidity or cognitive function. 
Patient characteristics  
The socio-demographic characteristics of patients are described in Table 1. Six months after 
the initial referral to the MAS, 83% had received a diagnosis. About half had been diagnosed 
with dementia, a quarter with MCI and 5% with various other diagnoses (including 
depression, alcohol related diagnosis, cerebrovascular diseases, syndromic conditions and 
other psychiatric diagnoses). 
Of those with dementia, 245 (55%) had Alzheimer’s disease, 104 (24%) mixed or unspecified 
dementia, 73 (17%) vascular dementia, 8 (2%) dementia with Lewy bodies, 8 (2%) 
Parkinson’s disease, and 3 (1%) fronto-temporal dementia.  
Use of post-diagnosis interventions 
Of 306 patients diagnosed with dementia and with data on use of post-diagnostic 
interventions, 186 (61%) were being treated with anti-dementia medications: donepezil 
(65%), memantine (19%), rivastigmine (11%), galantamine (2%) and unspecified (3%). 
Patients with a diagnosis of Alzheimer’s disease were most likely to be taking anti-dementia 
drugs (77%), while the lowest proportion of use was among those diagnosed with vascular 
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dementia (14%) (p<0.001). Use of anti-dementia drugs was higher among patients without 
comorbidities (72%) than those with comorbid conditions (58%) (p=0.04). Of the patients 
who were not diagnosed with dementia (and had data on use of post-diagnostic 
interventions, n=218), 12 (6%) had been prescribed an anti-dementia drug: 1% (n=1) of 
those with MCI, 24% (n=5) of those with other diagnosis, and 8% (n=6) of those with no 
diagnosis. 
Only 67 (22%) patients with dementia were using non-pharmacological interventions. Of 
these, 37 (55%) were also using anti-dementia drugs.  Most (73%) patients using non-
pharmacological interventions received one type of therapy or service, 21% two and 6% 
three or more. The most frequent were social engagement groups (used by 10%), memory 
cafes (4%), cognitive behaviour therapy (3%) and befriending services (3%). These 
interventions were also being used by 27 people (12%) who had not been diagnosed with 
dementia.  
Change in health related quality of life  
Patients on average reported their HRQL had improved between baseline and 6 months: 
mean DEMQOL score increased 3.4 points (95% CI 2.7 to 4.1), equivalent to an effect size of 
0.28 SD; EQ-5D score rose 0.02 (effect size: 0.07 SD). Carers also reported patient HRQL had 
improved, according to DEMQOL-Proxy, though by a smaller amount (1.3 points; effect size: 
0.14 SD) (Table 2).  
The pattern of improvement in self-reported HRQL (DEMQOL) was similar for those 
diagnosed with dementia, with MCI or with no diagnosis.  For self-reported EQ-5D 
improvement was only seen for those with a diagnosis of dementia.  For proxy-reported 
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HRQL (DEMQOL-Proxy), carers reported improvement only for those with a diagnosis of 
dementia or no diagnosis, and did not report improvement for those with MCI.  
Association between patient characteristics and change in HRQL 
Overall, change in HRQL over time was not associated with any patient characteristics in 
unadjusted or adjusted analyses, for both self-reported (Table 3) and proxy-reported 
measures of HRQL (Table 4). Similarly, cognitive function was not associated with changes in 
self-reported HRQL (DEMQOL score) or proxy-reported HRQL (DEMQOL-Proxy score) in 
adjusted analyses (Supplemental Table 1). 
Association between post-diagnostic interventions and change in HRQL in dementia  
Among patients diagnosed with dementia, greater improvement in self-reported HRQL was 
associated with use of anti-dementia medications in unadjusted and adjusted analyses 
(Table 5): the adjusted change in DEMQOL score was 3.3 points (95% CI 1.4 to 5.3) greater 
among patients using anti-dementia medications (effect size: 0.27 SD). Although there was 
no significant effect of non-pharmacological therapies on self-reported HRQL in unadjusted 
analyses, after adjustment a significantly smaller improvement  in DEMQOL score was 
observed compared to those who did not use these services: adjusted difference -2.4 points 
(95% CI -4.8 to -0.003; effect size: -0.20 SD). In both unadjusted and adjusted analyses, 
proxy-reported HRQL showed no significant association with either anti-dementia drugs or 
non-pharmacological therapies. 
Sensitivity analyses excluding cognitive function as a covariate from the multivariable model 
resulted in a smaller but still positive association between use of anti-dementia drugs and 
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improvement in HRQL (2.3 points, 95% CI 0.4 to 4.2; effect size: 0.19), while the effect size 
for non-pharmacological interventions was unchanged. 
DISCUSSION 
Main findings 
Over half of patients who were referred to MASs for memory problems were diagnosed 
with dementia, and a further quarter were diagnosed with MCI. HRQL among patients 
improved in the first six months after referral, irrespective of diagnosis. The magnitude of 
change was smaller for proxy-reported measures of HRQL than self-reported measures. 
Improvement in HRQL measured using EQ-5D (self- and proxy-reported) was smaller than 
that measured using DEMQOL and DEMQOL-Proxy, but EQ-5D has been shown to have poor 
construct validity for dementia, and condition-specific measures such as DEMQOL are 
recommended.26 Change in HRQL was not associated with any patient characteristics.  
Among patients who were diagnosed with dementia, 61% were being treated with anti-
dementia drugs and 22% were using non-pharmacological therapies. Anti-dementia drugs 
were associated with a greater improvement in self-reported HRQL whereas use of non-
pharmacological therapies was associated with a smaller improvement. Change in proxy-
reported HRQL did not show any association with use of pharmacological or non-
pharmacological interventions. In adjusted analyses, cognitive function at baseline was not 
associated with improvement in HRQL. 
Strengths and limitations 
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This is the largest published study of longitudinal change in HRQL among people referred to 
MASs. The sample is largely representative of MASs across the whole country and the 
patients attending them.17   
However, the study has four main limitations which impact on the interpretation of the 
findings. First, it is not possible to attribute the observed improvement in HRQL to MASs 
(diagnosis and post-diagnosis support), since we do not have comparable information on 
those people who were not referred. Due to the lack of clinical equipoise concerning early 
assessment and treatment for dementia, a control arm was not considered to be ethical. 
Second, only two-thirds of participants were followed up at six months. Respondents at six 
months follow-up were more likely than non-respondents to be more affluent and have 
better baseline cognitive function and proxy-reported HRQL. This may have led to 
overestimation of the improvement in self-reported HRQL since higher cognitive function 
was associated with greater improvement in unadjusted analyses. Third, data on cognitive 
function were missing for a fifth of participants. However, the proportion of missing values 
was not associated with most patient characteristics, with the exception of the number of 
comorbidities and use of non-pharmacological interventions. Sensitivity analyses excluding 
cognitive function as a covariate from the multivariable model did not change the 
conclusions of our analyses. Fourth, data on the use of post-diagnostic interventions 
(pharmacological and non-pharmacological) were not available for patients without a carer 
participating in the study. As these patients were more likely to be female, women 
diagnosed with dementia are likely to be underrepresented in our analysis of post-
diagnostic interventions.   
Comparisons with other studies 
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A previous study found that referral to a MAS improved HRQL at six months, but the study 
was confined to one service so its generalizability is uncertain.11 Based on their findings, 
Banerjee & Wittenberg modelled the likely cost-effectiveness of memory services which 
suggested a gain of 0.01-0.02 QALYs per person year would render the service cost-
effective.27  This is the approximate level of improvement reported over the first six months 
by patients and their carers in this study (based on EQ-5D index), suggesting referral to a 
MAS may be cost-effective. However, caution is required due to the study limitations 
described above, and the cost-effectiveness model only considered the benefit of 
preventing (delaying) admission to residential care and did not include direct costs of 
diagnostic investigations and post-diagnosis interventions. 
The absence of an association with cognitive function at baseline could suggest that 
improvement in HRQL is feasible in any stage from mild to moderate dementia. However, 
patients with lower cognitive function at baseline were less likely to be followed up at 6 
months, and it is possible that patients with the greatest deterioration in cognitive function 
are not represented in this sample. 
The level of use of anti-dementia drugs in those diagnosed with dementia (61%) is higher 
than that reported from general practice (35%).28 However, the latter includes both recently 
diagnosed patients and people with long-standing dementia in whom treatment may no 
longer be appropriate. There have been no studies of the frequency of uptake of non-
pharmacological post-diagnosis therapies with which our findings can be compared.29 The 
association between anti-dementia drug use and HRQL found in this study may be partly 
due to confounding by indications (or contraindications) for these medications; however, for 
those who are prescribed drugs, there appears to be a greater improvement in HRQL. 
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In experimental studies some non-pharmacological interventions have been shown to be 
effective in improving HRQL and other outcomes.29-31 There are several possible reasons for 
the lack of observed benefit of non-pharmacological interventions in our study, which relate 
to the interventions (heterogeneity of interventions included; the fidelity with which they 
were provided may not have been as high as in trials; duration of treatment too short for an 
effect to be apparent) and the patients (lack of compliance; inappropriate expectations of 
benefit leading to disappointment). There is also the possibility of a reverse causality effect, 
with patients who have experienced poorer HRQL following diagnosis potentially being 
more likely to be referred for such interventions.  
While our findings point to a potential role of both drugs and non-pharmacological 
interventions in affecting patients’ HRQL, more work is needed to understand the processes 
underlying changes in HRQL and the other factors that may explain these changes. We are 
currently undertaking work to explore the associations between service-level factors and 
HRQL, which may lead to the identification of potential mediators of change and contribute 
to our understanding of the mechanisms involved. 
Implications  
Assuming the observed improvement in HRQL reflects the benefits of what can be achieved 
in normal clinical practice in MASs (rather than the natural history of HRQL in dementia 
without any intervention), then this study provides evidence of the value of the current 
policy in many countries to encourage detection and intervention for people with memory 
problems. Further evidence regarding the underlying mechanisms of change and the 
sustainability of the benefits beyond six months is needed. The sample in this study is 
17 
currently being followed up after 12 months with plans for a further extension to five years 
being drawn up.  
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Table 1: Baseline characteristics and diagnosis of patients followed up at 6 months (n=883) 
Characteristic  Mean (SD) or n (%) 
Age (years) 77.6 (8.3) 
     <75 274 (31.0%) 
     75-79 198 (22.4%) 
     80-84 232 (26.3%) 
     ≥85 179 (20.3%) 
Sex  
     Male 436 (49.4%) 
     Female 447 (50.6%) 
Ethnicity  
     White/White British 833 (94.8%) 
     Other ethnicity 46 (5.2%) 
     Missing 4 
Deprivation quintiles  
     1 – least deprived 243 (27.9%) 
     2 189 (21.7%) 
     3 162 (18.6%) 
     4 159 (18.3%) 
     5 – most deprived 117 (13.5%) 
     Missing 13 
Number of comorbidities  
     0 183 (20.7%) 
     1 242 (27.4%) 
     2 216 (24.5%) 
     ≥3 241 (27.3%) 
     Missing 1 
Diagnosis  
     Dementia * 441 (53.5%) 
     MCI 202 (24.5%) 
     Other diagnosis 44 (5.3%) 
     No diagnosis took place 138 (16.7%) 
     Missing 58 
Cognitive function  
     1 – lowest function 272 (38.7%) 
     2 222 (31.6%) 
     3 – highest function 209 (29.7%) 
     Missing 180 
* Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, 
mixed or unspecified dementia, dementia in Parkinson’s disease  
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Table 2: Change in self- (n=883) and proxy-reported (n=569) patient HRQL in all patients with both baseline and 6 month scores and by diagnosis  
 Score at baseline  
Mean (SD) 
Score at 6 months  
Mean (SD)  
Mean change* (95% CI) 
    
   DEMQOL equated score  (n=875) 65.4 (12.3) 68.8 (12.7) 3.4 (2.7 to 4.1) 
     Dementia (n=436) 66.5 (12.8) 69.8 (12.7) 3.3 (2.3 to 4.3) 
     MCI (n=202) 65.7 (12.0) 68.7 (12.6) 3.0 (1.7 to 4.4) 
     No diagnosis (n=137) 64.1 (12.0) 67.0 (12.7) 2.9 (1.1 to 4.8) 
    
    EQ-5D-3L Index score (n=861) 0.71 (0.28) 0.73 (0.28) .02 (.01 to .04) 
    Dementia (n=428) 0.75 (0.25) 0.77 (0.24) .02 ( .01 to .05) 
    MCI (n=199) 0.70 (0.28) 0.71 (0.31) .01 (-.02 to .04) 
    No diagnosis (n=136) 0.67 (0.32) 0.68 (0.33) .01 (-.04 to .06) 
    
     DEMQOL-Proxy equated score  (n=563) 57.1 (9.4) 58.4 (10.6) 1.3 (0.5 to 2.1) 
     Dementia (n=308) 55.5 (9.1) 57.0 (10.4) 1.5 ( 0.5 to 2.5) 
      MCI (n=123) 59.6 (9.6) 59.8 (10.6) 0.2 (-1.4 to 1.9) 
    No diagnosis (n=80) 58.7 (9.5) 61.2 (10.9) 2.5 ( 0.6 to 4.5) 
    
    EQ-5D-3L Proxy Index score  (n=538) 0.62 (0.31) 0.60 (0.32) -.02 (-.04 to .003) 
    Dementia (n=293) 0.60 (0.30) 0.57 (0.32) -.03 (-.06 to .004) 
     MCI (n=117) 0.68 (0.30) 0.65 (0.31) -.03 (  -.08 to .02) 
     No diagnosis (n=75) 0.62 (0.33) 0.63 (0.32) .01 (  -.05 to .08) 
*Positive change score indicates improvement in HRQL. Figures in bold p<0.05. 
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Table 3: Change in DEMQOL equated score by patient characteristics (linear regression analyses) 
Patient characteristics Number DEMQOL equated 
score at 6 months 
Mean (SD) 
Change (SD) in 
DEMQOL equated 
score 
 
Unadjusted 
difference in 
change * 
Adjusted 
difference in 
change † 
(95% CI with 
Bonferroni 
correction) 
Age (years)       
<75 273 65.8 (12.7) 3.5 (9.8) Reference Reference  
75-79 197 69.9 (13.2) 5.1 (10.6) 1.5 2.2 (-0.6 to 5.0) 
80-84 229 70.2 (12.6) 2.3 (10.5) -1.2 0.04 (-2.6 to 2.7) 
≥85 177 70.6 (11.7) 2.7 (10.3) -0.8 0.7 (-2.0 to 3.3) 
Sex       
Male 433 68.3 (12.9) 3.2 (10.3) Reference Reference  
Female 442 69.4 (12.5) 3.6 (10.3) 0.4 1.0 (-1.3 to 3.3) 
Ethnicity        
White/White British 826 68.9 (12.8) 3.3 (10.4) Reference Reference  
Other ethnicity 46 68.1 (11.9) 5.0 (9.3) 1.8 0.5 (-3.6 to 4.7) 
Deprivation (quintiles of IMD)       
1 – least deprived 239 70.1 (12.2) 2.7 (10.2) Reference Reference  
2 188 68.6 (13.1) 3.5 (10.2) 0.8 0.2 (-3.1 to 3.4) 
3 161 69.6 (12.0) 3.9 (9.9) 1.2 1.1 (-1.6 to 3.8) 
4 157 66.7 (13.0) 3.9 (10.2) 1.2 -.001 (-2.9 to 2.9) 
5 – most deprived 117 68.8 (13.6) 3.3 (10.9) 0.6 0.4 (-3.1 to 3.9) 
Number of comorbidities       
0  181 69.1 (12.5) 2.9 (11.2) Reference Reference  
1 242 70.3 (11.6) 4.4 (9.7) 1.5 1.5 (-1.5 to 4.4) 
2 214 69.5 (13.0) 3.2 (10.4) 0.3 0.3 (-2.9 to 3.7) 
3 or more 238 66.5 (13.6) 2.8 (10.1) -0.1 -0.8 (-4.4 to 2.7) 
* Positive change score indicates improvement in HRQL. Adjusted for clustering by clinic; † Adjusted for age, sex, ethnicity, deprivation, number of 
comorbidities, diagnosis, DEMQOL score at baseline and clustering by clinic, n=804 with complete data on all variables. 
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Table 4: Change in DEMQOL-Proxy equated score by patient characteristics (linear regression analyses) 
Patient characteristics Number  DEMQOL-Proxy 
equated score at 6 
months. Mean (SD) 
DEMQOL-Proxy 
equated score 
change (SD) 
Unadjusted 
difference in 
change * 
Adjusted 
difference in 
change † 
(95% CI with 
Bonferroni 
correction) 
Age (years)       
<75 172 59.0 (11.0) 2.2 (9.3) Reference Reference  
75-79 142 58.4 (9.5) 1.3 (8.2) -0.9 -0.9 (-3.8 to 2.1) 
80-84 148 57.4 (10.6) -0.4 (9.5) -2.6 -2.1 (-6.6 to 2.4) 
≥85 104 58.9 (11.4) 2.2 (10.8) -0.01 -0.06 (-4.5 to 4.3) 
Sex       
Male 307 59.2 (10.5) 1.3 (9.0) Reference Reference  
Female 256 57.5 (10.7) 1.3 (9.8) 0.03 -0.5 (-3.0 to 1.9) 
Ethnicity       
White/White British 540 58.5 (10.6) 1.2 (9.3) Reference Reference  
Other ethnicity 23 56.0 (11.8) 4.4 (10.8) 3.2 1.4 (-5.2 to 7.9) 
Deprivation (quintiles of IMD)       
1 – least deprived 154 58.7 (9.4) 0.6 (7.3) Reference Reference  
2 121 58.0 (9.2) 1.0 (8.4) 0.4 0.1 (-2.6 to 2.9) 
3 108 59.0 (10.6) 0.7 (10.6) 0.1 1.0 (-2.4 to 4.4) 
4 104 58.5 (13.2) 2.3 (11.1) 1.7 0.9 (-2.2 to 4.0) 
5 – most deprived 69 57.7 (11.5) 2.9 (10.6) 2.3 1.2 (-2.8 to 5.2) 
Number of comorbidities       
0  111 59.6 (10.5) 0.5 (9.3) Reference Reference  
1 146 58.0 (10.3) 1.6 (8.6) 1.1 0.2 (-2.8 to 3.2) 
2 148 59.2 (10.4) 1.1 (9.0) 0.6 0.2 (-2.8 to 3.2) 
3 or more 158 57.3 (11.1) 1.8 (10.6) 1.2 0.2 (-3.6 to 4.1) 
* Positive change score indicates improvement in HRQL. Adjusted for clustering by clinic; † Adjusted for age, sex, ethnicity, deprivation, number of 
comorbidities, diagnosis, DEMQOL-Proxy score at baseline and clustering by clinic, n=524. 
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Table 5: Change in HRQL among patients with dementia diagnosis by post-diagnosis interventions (random effects model) 
 Number 
with 
outcome 
Score at 6 
months 
(SD) 
DEMQOL 
equated score 
change (SD) 
Unadjusted 
difference in 
change * 
Adjusted 
difference in 
change † 
(95% CI) 
Self-reported DEMQOL        
Anti-dementia medications       
No 116 68.8 (12.1) 2.2 (10.7) Reference Reference  
Yes 187 70.3 (13.2) 4.6 (10.0) 2.4 3.3 (1.4 to 5.3) 
Non-pharmacological therapies        
No 238 70.9 (13.0) 3.8 (11.0) Reference Reference  
Yes 67 65.4 (11.5) 2.4 (7.5) -1.4 -2.4 (-4.8 to -.003) 
       
Proxy-reported DEMQOL        
Anti-dementia medications       
No 111 56.8 (11.1) 0.8 (9.5) Reference Reference  
Yes 182 57.6 (10.0) 2.1 (8.9) 1.3 1.4 (-1.1 to 3.9) 
Non-pharmacological therapies        
No 234 57.8 (10.6) 1.8 (9.6) Reference Reference  
Yes 61 55.5 (9.4) 1.5 (7.4) -0.3 -0.3 (-2.8 to 2.2) 
Positive change score indicates improvement in HRQL. * Adjusted for clustering by clinic; † Adjusted for age, sex, ethnicity, deprivation, number of 
comorbidities, cognitive function, HRQL at baseline and clinic as a random effect. (In addition, medications adjusted for non-pharmacological therapies and 
vice versa). Coefficients in bold p<0.05. 
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Supplemental Figure 1. Flow chart showing sample sizes in MAS Study at baseline, three- and six-
month follow up 
 
80 MAS 
(random sample) 
2 MASs did not participate 
MASs Patients/carers 
BASELINE MAIN ANALYSIS SAMPLE 
73 MAS                                               1420 patients 
                                                                    1020 carers 
ELIGIBLE FOR SIX MONTH FOLLOW UP 
69 MAS                                                 1318 patients  
                                                      944 carers 
4 MASs did not participate 67 patients, 54 carers 
SIX MONTHS 
69 MAS                                      883 (67%) patients  
                                                           569 (60%) carers 
435 patients, 375 carers no response 
35 patients died, 22 carers 
BASELINE 
78 MAS                                               1434 patients 
                                                                    1030 carers 
5 MASs recruited 5 or fewer patients 14 patients, 10 carers 
THREE MONTHS 
73 MAS   658 (65%) carers 
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Supplemental Table 1: Change in HRQL among patients with dementia diagnosis by cognitive function at baseline (random effects model) 
 Cognitive function 
 1 – lowest  2- mid  3 – highest  
DEMQOL equated score     
Number 203 111 45 
Change (SD) 2.0 (11.4) 4.7 (8.8) 3.6 (9.5) 
Unadjusted difference in change * (95% CI) Reference 2.7 (0.3 to 5.1) 1.5 (-1.8 to 4.9) 
               Adjusted difference in change † (95% CI) Reference 1.5 (-1.0 to 4.0) -0.7 (-4.8 to 3.5) 
    
DEMQOL-Proxy equated score     
Number 144 80 29 
Change (SD) 1.7 (10.1) 1.9 (9.2) 0.1 (5.7) 
Unadjusted difference in change *(95% CI) Reference 0.2 (-2.4 to 2.8) -1.6 (-5.4 to 2.2) 
               Adjusted difference in change † (95% CI) Reference -0.003 (-2.7 to 2.7) -2.5 (-5.1 to 0.1) 
Positive change score indicates improvement in HRQL. * Adjusted for clustering by clinic; † Adjusted for age, sex, ethnicity, deprivation, number of 
comorbidities,  medications, use of non-pharmacological therapies, HRQL score at baseline and clinic as a random effect. Coefficients in bold p<0.05. 
 
 
